Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.12
+$0.02 · +0.95%
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Previous close
$2.12
+$0.02 · +0.95%
Regular session · ET · Market data may be delayed.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Day range
Current $2.12
52-week range
Current $2.12
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
56
Mixed
Risk
89
Extreme Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Day range
Current $2.12
52-week range
Current $2.12
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 70M USD | — | — | — | — |
| Cost of goods sold | 325K USD | — | 437K USD | — | — |
| Gross profit | 69.68M USD | — | −437K USD | — | — |
| Research and development | 33.56M USD | 51.31M USD | 58.91M USD | 64.44M USD | 96.83M USD |
| Selling, general, and administrative | 16.57M USD | 27.47M USD | 27.11M USD | 28.39M USD | 30.04M USD |
| Operating expenses | 49.81M USD | 78.78M USD | 86.02M USD | 92.83M USD | 126.87M USD |
| Interest income | 4.06M USD | 2.18M USD | 1.92M USD | 2.03M USD | 3.46M USD |
| Depreciation and amortization | 325K USD | 343K USD | 437K USD | 508K USD | 205K USD |
| Operating income | 19.87M USD | −78.78M USD | −86.46M USD | −92.83M USD | −126.87M USD |
| Net income | 22.37M USD | −69.68M USD | −82.44M USD | −91.17M USD | −125.6M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.83
458.02% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.63M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM2.5M0.00%80.51B USD0.19%$296.01+0.28%
Fidelity Enhanced Small Cap ETFFESM1.26M0.02%6.03B USD0.28%$47.36+0.21%
iShares U.S. Small-Cap Equity Factor ETFSMLF968.97K0.02%4.27B USD0.15%$88.15+0.20%
iShares Russell 2000 Value ETFIWN968.93K0.01%14.61B USD0.24%$224.62+0.40%
Vanguard Extended Market ETFVXF864.01K0.00%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB772.39K0.01%10.73B USD0.44%$211.92-0.88%
EA Bridgeway Omni Small-Cap Value ETFBSVO570K0.02%1.71B USD0.47%$29.88+0.95%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMiShares U.S. Small-Cap Equity Factor ETFSMLFiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBEA Bridgeway Omni Small-Cap Value ETFBSVOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
